16th International Lung Cancer Congress

The Next Generation of Agents for Lung Cancer

At the 16th Annual International Lung Cancer Congress, Tony Mok, MD, Professor of Clinical Oncology, The Chinese University of Hong Kong, provided an overview of the next generation of agents, taking stock of the recent past for insights into the future of drug discovery. Drug discovery is rarely, if ever, [ Read More ]

Immunotherapy Will Alter the NSCLC Treatment Landscape

Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation and thus become resistant when treated with a tyrosine kinase inhibitor. According to data presented at the congress, however, lung cancer remains a highly mutated disease, suggesting great potential for immunotherapy. “If [ Read More ]

Looking into the Future of Lung Cancer Research

Each year, the Bonnie J. Addario Lung Cancer Foundation (ALCF) recognizes luminaries in the quest to cure lung cancer with the Addario Lectureship Award. This year, Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, University of Colorado School of Medicine, Denver, delivered his keynote lecture on the many [ Read More ]

Sign me up!